SIM 0718
Alternative Names: SIM-0718Latest Information Update: 17 Jul 2024
At a glance
- Originator Simcere Pharmaceutical Group
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Atopic dermatitis
Most Recent Events
- 17 Jul 2024 Simcere Pharmaceutical plans a phase III trial in Asthma (In Adolscents, In adults, In the elderly) in July 2024 in China (SC, Injection) (NCT06488755)
- 05 Jul 2024 Investigation in Atopic dermatitis (SC) prior to October 2024.
- 05 Jul 2024 Simcere Pharmaceutical group plans a phase III trial for Atopic dermatitis (In Adolscents, In adults, In the elderly) in October 2024 (SC, Injection) (NCT06477835)